Overview

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Status:
Not yet recruiting

Trial end date:
2024-04-30

Target enrollment:

Participant gender:

Summary

This study is a randomized, double-blind, placebo-controlled, multi-center clinical study. Target population is patients with stage IV non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of Camrelizumab + carboplatin/cisplatin + pemetrexed /paclitaxel / albumin paclitaxel ± SRT/WBRT with placebo + carboplatin/cisplatin + pemetrexed /paclitaxel / albumin paclitaxel ± SRT/WBRT. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Phase:

Phase 3

Details

Lead Sponsor:

Guangdong Association of Clinical Trials

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Pemetrexed